TABLE 1.
Patient Demographics
| Demographic | ICI-Treated Cohort at Mayo (N = 9,290) | ICI-Treated MEPS Cohort at Mayo (N = 314) |
|---|---|---|
| Age at first ICI initiation, years | ||
| Mean (SD), median | 64.44 (13.25), 66 | 64.41 (12.80), 66 |
| Sex, No. (%) | ||
| Male | 5,469 (58.9) | 175 (55.6) |
| Female | 3,821 (41.1) | 139 (44.1) |
| Race, No. (%) | ||
| Asian | 173 (1.9) | 2 (0.6) |
| Black or African American | 233 (2.5) | 6 (1.9) |
| Chose not to disclose | 83 (0.9) | 0 (0) |
| Native American/Pacific Islander | 52 (0.6) | 0 (0) |
| Other | 135 (1.5) | 8 (2.5) |
| Unknown | 44 (0.5) | 1 (0.3) |
| White | 8,570 (92.2) | 297 (94.3) |
| Ethnicity, No. (%) | ||
| Hispanic or Latino | 267 (2.9) | 10 (3.2) |
| Not Hispanic or Latino | 8,764 (94.3) | 298 (94.6) |
| Chose not to disclose | 145 (1.6) | 4 (1.3) |
| Unknown | 114 (1.2) | 2 (0.6) |
| Cancer types, No. (%) | ||
| Bladder | 422 (4.5) | 8 (2.5) |
| Breast | 217 (2.3) | 20 (6.4) |
| Colorectal | 187 (2.0) | 4 (1.6) |
| Liver | 254 (2.7) | 6 (1.9) |
| Lung | 1,720 (18.5) | 128 (40.8) |
| Renal | 544 (5.9) | 25 (7.9) |
| Skin | 1,918 (20.6) | 89 (28.3) |
| Other | 1,640 (17.7) | 43(13.7) |
| Unspecified | 2,482 (26.7) | 2 (0.6) |
| Therapy type, No. (%) | ||
| ICI monotherapy | 8,687 (93.51) | 287 (91.4) |
| ICI combination therapy | 786 (8.46) | 39 (12.4) |
Abbreviations: ICI, immune checkpoint inhibitor; MEPS, myocarditis, encephalitis, pneumonitis, and severe cutaneous adverse reactions; SD, standard deviation.